ISL
GCVRZ

Ingalls & Snyder LLC’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Ingalls & Snyder LLC’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$5K – 463
2018
Q2 		$5K Sell
10,000
-5,000
-33% -$2.33K ﹤0.01% 412
2018
Q1 		$6K Hold
15,000
– – ﹤0.01% 404
2017
Q4 		$6K Hold
15,000
– – ﹤0.01% 401
2017
Q3 		$5K Hold
15,000
– – ﹤0.01% 364
2017
Q2 		$6K Sell
15,000
-310
-2% -$127 ﹤0.01% 365
2017
Q1 		$7K Hold
15,310
– – ﹤0.01% 407
2016
Q4 		$6K Sell
15,310
-40
-0.3% -$14 ﹤0.01% 410
2016
Q3 		$4K Hold
15,350
– – ﹤0.01% 417
2016
Q2 		$4K Buy
+15,350
New +$2.64K ﹤0.01% 425

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Ingalls & Snyder LLC's GCVRZ Position: Q3 2018 in Review

Ingalls & Snyder LLC sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2018, closing a stake of 10,000 shares — an estimated $5K sold.

Ingalls & Snyder LLC first reported a position in GCVRZ in Q2 2016 and held it in 9 quarters. The position peaked at $7K in Q1 2017. 106 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2018.

  • Ingalls & Snyder LLC reported no remaining Sanofi Contingent Value Rights position as of Q3 2018 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 10,000 Sanofi Contingent Value Rights shares in Q3 2018, an estimated $5K.
  • Ingalls & Snyder LLC first reported a position in Sanofi Contingent Value Rights in Q2 2016 and held it in 9 quarters.
  • Ingalls & Snyder LLC's Sanofi Contingent Value Rights position peaked at $7K in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2018.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2018, filed 24 Oct 2018.